Possibly specific immune complexes in sera of patients with untreated acute myelogenous leukemia

Fäldt, R.; Ankerst, Jaro

doi:10.1002/ijc.2910260309

Cited by 8 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence for the presence of specific immune complexes in sera of patients with untreated AML, containing potentially cytotoxic antibodies against autochthonous leukemic cells, has been previously presented by ourselves [10]. Second, it is known from other malignant diseases that tumors may produce soluble antigens with the same specificity as those on the cell membranes.…”

Section: [181mentioning

confidence: 92%

A 125I-protein A-binding assay detecting antibodies to cell surface antigens

Fäldt

Ankerst

1983

Cancer Immunol Immunother

Self Cite

View full text Add to dashboard Cite

A 125I-protein A-binding assay detecting antibodies to cell surface antigens on human blood cells was developed and evaluated using sera from multitransfused nonleukemic patients sensitized against HLA antigens. The binding assay was found to be reproducible and more sensitive than conventional HLA testing. Seven patients with acute myelogenous leukemia and two patients with acute lymphoblastic leukemia successfully treated by chemotherapy were then investigated. Sera from seven of the patients studied in partial or complete remission demonstrated significant binding to autochthonous leukemic cells obtained from bone marrow or peripheral blood. In two cases sera taken during the leukemic stage demonstrated the most pronounced binding to the patients' own leukemic cells. Sera from four patients with demonstrable significant binding to autochthonous leukemic cells failed to bind to autochthonous remission cells when both types of target cells were tested in parallel. Differences in serum concentrations of IgG, IgA, and IgM were not the cause of the demonstrated increased binding of leukemic sera to autochthonous target cells. We propose that the 125I-protein A-binding assay presented in this paper detects antibodies reacting selectively with acute leukemia cells.

show abstract

Section: [181mentioning

confidence: 92%

A 125I-protein A-binding assay detecting antibodies to cell surface antigens

Fäldt

Ankerst

1983

Cancer Immunol Immunother

Self Cite

View full text Add to dashboard Cite

show abstract

“…We therefore find complete lack of a monocyte-supporting factor unlikely, and belive that the observed impairment of monocytemediated cytotoxicity is due to suppressive factors. Such factors might be tumour antigens (Baldwin & Price 1976), other tumour cell products (Normann & Snorkin 1977) or immune complexes (Faldt & Ankerst 1980). Soluble factors due to neoplasia with a suppressive effect on monocyte function have been demonstrated in serum (Rhodes et a1 1979), in ascites fluid (Mantovani et a1 1979(Mantovani et a1 , 1980, and in the medium of tumour cell cultures (Moldoveanu et a1 1978, Nelson & Nelson 1978.…”

Section: Scand J Haematol(l982) 29mentioning

confidence: 99%

Inhibitory Effect on Monocyte‐Mediated Cytotoxicity of Sera from Patients with Multiple Myeloma and Malignant Lymphoma

Eggen¹,

Lamvik²,

Unsgaard³

1982

Scandinavian Journal of Haematology

View full text Add to dashboard Cite

There was no difference in monocyte‐mediated cytotoxicity between monocytes from patients with multiple myeloma or malignant lymphomas and monocytes from control persons after in vitro culture for 5 d. Cytostatic and cytolytic ability of lymphokine‐activated monocytes cultured in medium with patient serum was significantly depressed compared to the ability of monocytes cultured with normal serum. A similar depression of cytostasis was found with non‐activated monocytes of both patient and control origin. Sera from myeloma and lymphoma patients impaired the monocyte‐mediated cytotoxicity equally.

show abstract

Antigens and circulating immune complexes related to the primate retroviral glycoprotein SiSVgp70: Indicators of early mortality in human acute leukemias and chronic myelogenous leukemias in blast crisis

Hehlmann

Erfle²,

Schetters

et al. 1984

Cancer

View full text Add to dashboard Cite

Human sera contain antigens and also circulating immune complexes that are related to the primate retroviral envelope glycoprotein gp70 of simian sarcoma/simian sarcoma associated virus (SiSV) and of gibbon ape leukemia virus (GaLV). SiSVgp70 related antigens (AG) and immune complexes (IC) are detected both in leukemic and in nonleukemic sera.23 In a further analysis of these data, the prognostic significance of SiSVgp70 related AG and IC indicates an unfavorable clinical course and a shorter survival time in acute leukemias (AL) and in chronic myelogenous leukemia in blast crisis (CML‐BC). Survival data of 56 of 64 patients tested were analyzed (38 patients with AL and 18 patients with CML‐BC). Patients with AL whose sera were positive for SiSVgp70 realted AG and IC had a median survival time of 9.5 months after diagnosis versus 16 months for patients negative for such AG and IC. This difference in survival time was more pronounced for patients with acute nonlymphocytic leukemia (ANLL) (6.5 versus 19 months). The difference in survival between SiSVgp70 related AG‐ and IC‐negative and positive groups as tested by life table analysis (log‐rank test) is significant (P < 0.05). Patients with AL of the AG‐ and/or IC‐positive group had fewer complete remissions. Patients who had no remissions belong to the AG‐ and/or IC‐positive group (P = 0.06). Patients with CML‐BC whose sera were positive for SiSVgp70 related AG and/or IC had a median survival time of 2 months after diagnosis versus 7 months for patients with sera negative for such AG and IC. As tested by long‐rank test, survival curves between the two groups are significantly different (P < 0.05). These findings suggest that SiSVgp70 related AG and IC may play an important role in the course of acute leukemia and can provide useful prognostic information.

show abstract

Possibly specific immune complexes in sera of patients with untreated acute myelogenous leukemia

Cited by 8 publications

References 6 publications

A 125I-protein A-binding assay detecting antibodies to cell surface antigens

A 125I-protein A-binding assay detecting antibodies to cell surface antigens

Inhibitory Effect on Monocyte‐Mediated Cytotoxicity of Sera from Patients with Multiple Myeloma and Malignant Lymphoma

Antigens and circulating immune complexes related to the primate retroviral glycoprotein SiSVgp70: Indicators of early mortality in human acute leukemias and chronic myelogenous leukemias in blast crisis

Contact Info

Product

Resources

About